ABSTRACT
Bacterial vaginosis (BV) is associated with HIV acquisition and adverse pregnancy outcomes. Recurrence after metronidazole treatment is high. HIV-negative, non-pregnant Rwandan BV patients were randomized to four groups (n=17/group) after seven-day oral metronidazole treatment: behavioral counseling only (control), or counseling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal capsule (containing multiple Lactobacillus and one Bifidobacterium species), or Gynophilus LP vaginal tablet (L. rhamnosus 35) for two months. Vaginal microbiota assessments at all visits included Gram stain Nugent scoring and 16S rRNA gene qPCR and HiSeq sequencing. All interventions were safe. BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in the metronidazole (1.41/person-year; p=0.004), Ecologic Femi+ (3.58/person-year; p=0.043), and Gynophilus LP groups (5.36/person-year; p=0.220). In mixed effects models adjusted for hormonal contraception/pregnancy, sexual risk-taking, and age, metronidazole and Ecologic Femi+ users, each compared to controls, had higher Lactobacillus and lower BV-anaerobes concentrations and/or relative abundances, and were less likely to have a dysbiotic vaginal microbiota type by sequencing. Inter-individual variability was high and effects disappeared soon after intervention cessation. Lactobacilli-based vaginal probiotics warrant further evaluation because, in contrast to antibiotics, they are not expected to negatively affect microbiota or cause antimicrobial resistance.
Competing Interest Statement
AN is employed by Biose (owner of trial product GynLP) and EL by Winclove Probiotics BV (owner of trial product EF+). These two companies did not provide funding for the trial but did donate their products for use in the trial free of charge. AN and JR have financial and/or intellectual investments in competing products. The other authors report no competing interests.
Clinical Trial
ClinicalTrials.gov: NCT02459665
Funding Statement
This work was funded by the DFID/MRC/Wellcome Trust Joint Global Health Trials Scheme as a Development Project (grant reference MR/M017443/1; grant title: "Preparing for a clinical trial of interventions to maintain normal vaginal microbiota for preventing adverse reproductive health outcomes in Africa") and the University of Liverpool (Technology Directorate Voucher). Vaginal probiotics for use in the trial were donated free of charge by Winclove Probiotics (Amsterdam, The Netherlands) and Biose (formerly Probionov, Aurillac, France). The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the authors’ institutions or companies, or the funders.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
NA
Data Availability
All data will be made available via the University of Liverpool Data Research Catalogue (https://datacat.liverpool.ac.uk/) with publication of the manuscript in a peer-reviewed journal. We prefer to do this after peer-review because the peer-review may result in additional analyses. The most essential data are included in the manuscript and in Supplements 1 and 2.
